What is the prognosis for patients treated with eculizumab for aHUS?

See full prescribing information for Soliris. Soliris™ (eculizumab),. Concentrated solution for intravenous infusion. Initial U.S. Approval: 2007. WARNING: ... NMOSD patients receiving Soliris should be monitored for early signs of meningococcal infection. No ongoing monitoring is recommended following discontinuation ... About This Drug. Eculizumab-xxxx (Soliris, Bkemv) is used to treat some blood disorders and nerve disorders. It is given in the vein (IV). View the fact sheet ... Apr 7, 2025 ... ... Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris ® in the U.S. Teva and Samsung Bioepis entered into ... Aetna considers eculizumab, or its biosimilar, medically necessary for any of the following indications when criteria are met: Aug 15, 2018 ... Reported relapse rates in aHUS after stopping eculizumab are as high as 30%, suggesting indefinite therapy is reasonable and that patients who choose to stop ... Simple Search Results for: SolirisNew SearchNavigate to Advanced Search ; Biosimilar(s) · Epysqli · eculizumab-aagh ; Interchangeable(s) · Bkemv · eculizumab-aeeb. Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody drug eculizumab (Soliris) using ready-made anti-idiotypic antibodies. Mar 7, 2025 ... Soliris, whose active substance is eculizumab, is a first‐in‐class biologic therapy designed to inhibit a key protein in the complement cascade— ... As anti-C5 therapy like eculizumab is the only treatment for patients with aHUS, optimizing treatment is indispensable. The drug label states that a trough ...